Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Genzyme |
---|---|
Information provided by: | Genzyme |
ClinicalTrials.gov Identifier: | NCT00069862 |
A clinical trial designed to compare the safety and iron excretion properties of desferoxamine (DFO) and deferitrin (GT56-252), an experimental oral iron chelator.
Condition | Intervention | Phase |
---|---|---|
Beta-Thalassemia |
Drug: Deferitrin (GT56-252) Drug: desferoxamine (DFO) |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Crossover Assignment, Safety/Efficacy Study |
Official Title: | Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | GTC-134-102 |
Study First Received: | October 2, 2003 |
Last Updated: | June 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00069862 |
Health Authority: | United States: Food and Drug Administration |
Beta Thalassemia |
Metabolic Diseases Hematologic Diseases Beta-thalassemia Anemia Anemia, Hemolytic Iron Metabolism Disorders Thalassemia Anemia, Hemolytic, Congenital Thalassemia minor |
Genetic Diseases, Inborn Beta-Thalassemia Hemoglobinopathies Neoplasm Metastasis Iron Overload Metabolic disorder Hemoglobinopathy Iron |